Citigroup Inc Neurocrine Biosciences Inc Transaction History

Citigroup Inc

$217 Billion
Q3 2025

A detailed history of Citigroup Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Citigroup Inc holds 237,082 shares of NBIX stock, worth $34.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

237,082

Previous 322,064 26.39%

Holding current value

$34.3 Million

Previous $40.5 Million 17.78%

% of portfolio

0.02%

Previous 0.02%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	$123.98 - $146.67 $10.5 Million - $12.5 Million	-84,982 Reduced 26.39%	237,082 $33.3 Million
Q2 2025 Aug 11, 2025	SELL	$87.54 - $128.18 $12.6 Million - $18.5 Million	-144,125 Reduced 30.92%	322,064 $40.5 Million
Q1 2025 May 12, 2025	BUY	$107.22 - $153.29 $32.3 Million - $46.1 Million	301,009 Added 182.23%	466,189 $51.6 Million
Q4 2024 Feb 12, 2025	SELL	$111.62 - $139.44 $3.94 Million - $4.93 Million	-35,339 Reduced 17.62%	165,180 $22.5 Million
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $9.65 Million - $12.9 Million	84,230 Added 72.43%	200,519 $23.1 Million

Q2 2024 Aug 12, 2024	SELL	$130.86 - $143.19 $5.08 Million - $5.55 Million	-38,789 Reduced 25.01%	116,289 $16 Million
Q1 2024 May 10, 2024	SELL	$130.4 - $143.74 $2.2 Million - $2.42 Million	-16,855 Reduced 9.8%	155,078 $21.4 Million
Q4 2023 Feb 09, 2024	SELL	$106.07 - $132.76 $1.9 Million - $2.38 Million	-17,915 Reduced 9.44%	171,933 $22.7 Million
Q3 2023 Nov 09, 2023	SELL	$94.02 - $117.1 $1.81 Million - $2.26 Million	-19,273 Reduced 9.22%	189,848 $21.4 Million
Q2 2023 Aug 10, 2023	SELL	$89.53 - $104.87 $865,396 - $1.01 Million	-9,666 Reduced 4.42%	209,121 $19.7 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $7.61 Million - $9.94 Million	80,811 Added 58.57%	218,787 $22.1 Million
Q4 2022 Feb 09, 2023	BUY	$106.72 - $127.06 $255,060 - $303,673	2,390 Added 1.76%	137,976 $16.5 Million
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $3.74 Million - $4.39 Million	40,677 Added 42.86%	135,586 $14.4 Million
Q2 2022 Aug 10, 2022	BUY	$75.79 - $100.07 $2.51 Million - $3.31 Million	33,104 Added 53.56%	94,909 $9.25 Million
Q1 2022 May 12, 2022	SELL	$72.45 - $94.81 $3.26 Million - $4.26 Million	-44,956 Reduced 42.11%	61,805 $5.79 Million
Q4 2021 Feb 10, 2022	BUY	$79.65 - $106.22 $3.45 Million - $4.6 Million	43,336 Added 68.33%	106,761 $9.09 Million
Q3 2021 Nov 10, 2021	BUY	$86.18 - $99.03 $5.47 Million - $6.28 Million	63,425 New	63,425 $6.08 Million

Others Institutions Holding NBIX

# of Institutions

731

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account